Oxford BioTherapeutics and Berlin Chemie/Menarini update on $1 billion oncology investment alliance

UK biotech firm Oxford BioTherapeutics (OBT) and family-owned Italian Berlin Chemie/Menarini Group have designated a novel antibody-drug conjugate (ADC) targeting non-Hodgkin’s B-cell lymphoma and solid tumors, including some subsets of breast cancers, where the target is expressed, as the second clinical development candidate under the companies’ strategic $1 billion oncology partnership. The ADC is currently undergoing formal regulatory enabling studies to support an application for the future clinical phase.

The ADC candidate is a novel antibody-based therapeutic against an undisclosed cancer target identified by OBT’s proprietary OGAP discovery technology and has completed in vivo proof-of-concept in several solid and liquid tumor models and exploratory toxicology testing. The therapeutic incorporates proven ADC technology developed by ImmunoGen, and has successfully completed preclinical in vivo proof-of-concept and exploratory toxicology testing.

Further milestone for Oxford Bio